Biopharma financing and deals 2026

Timeline

1. 2 days ago

   [BUSINESS] 17 sources

   AbbVie Q2 2026 earnings beat forecasts and announces Apogee Therapeutics acquisition

   AbbVie posted Q2 2026 earnings beat forecasts, announced a $10.9 bn Apogee acquisition, and trimmed its profit outlook; Ferrari continued its €3.5 bn buyback, while Brookfield Renewable, Alliant Energy, Brookif

2. 12 days ago

   [BUSINESS] 3 sources

   AbbVie to Acquire Apogee Therapeutics for $10.9 Billion

   AbbVie announced a $10.9 billion cash acquisition of Apogee Therapeutics, adding an eczema drug and financing it with debt; analysts rate Apogee shares as Hold with price targets near $130.

3. 16 days ago

   [BUSINESS] 5 sources

   Angelini Pharma completes $4.1bn buyout of U.S. rare‑disease firm Catalyst

   Angelini Pharma completed a $4.1 bn purchase of U.S. rare‑disease company Catalyst, financed by CDP Equity and Blackstone, to expand its global foothold in neurological and rare‑disease medicines.

4. 20 days ago

   [BUSINESS] 2 sources

   Vertex Pharmaceuticals' $10 B Acquisition of Crinetics Expands Endocrinology Portfolio

   Vertex to buy Crinetics for $10 billion, gaining oral acromegaly drug PALSONIFY and CAH candidate atumelnant; analysts adjust Crinetics ratings amid integration concerns.

5. 22 days ago

   [BUSINESS] 2 sources

   FDA approvals spur deals and pipeline expansions for pharma firms

   FDA cleared new drugs from Johnson & Johnson, Vera, AbbVie‑Genmab and Accord BioPharma, while Vertex announced a $10 bn Crinetics acquisition and other pharma firms struck major deals.

6. 25 days ago

   [BUSINESS] 2 sources

   Abivax completes $920 million public offering

   Abivax SA closed a $920 million public offering of 7.36 million ADS, netting about $874 million to fund operations through Q4 2029; shares trade on Nasdaq and Euronext Paris.

7. 26 days ago

   [BUSINESS] 2 sources

   United Therapeutics acquires Thymmune Therapeutics for $140 million

   United Therapeutics bought Thymmune Therapeutics for $140 million cash, with up to $160 million in milestone payments, adding a thymic cell‑therapy platform targeting congenital athymia and immune disorders.

8. about 1 month ago

   [BUSINESS] 2 sources

   Abivax raises $800 million, valuation climbs to $11 billion

   Abivax secured $800 million in a share sale, boosting its valuation to about $11 billion and giving it flexibility ahead of a possible future sale.

9. about 1 month ago

   [BUSINESS] 2 sources

   Zymeworks to Acquire Theravance Biopharma for $929 Million

   Zymeworks is buying Theravance Biopharma for $929 million to add the COPD drug Yupelri to its portfolio, aiming for new cash flow and market expansion.

10. about 1 month ago

    [BUSINESS] 2 sources

    Biogen cuts Apellis research programs after $5.6 bn acquisition

    Biogen paused most Apellis research, cut some research staff and shifted focus to Empaveli and Syfovre after its $5.6 bn acquisition.

11. about 1 month ago

    [BUSINESS] 3 sources

    Amgen and Iovance biotech stocks weighed as investors eye growth and stability

    Amgen posted $36.7 bn revenue and strong profit, while Iovance saw rapid revenue growth but a $391 m loss. AbbVie’s $10.9 bn buy‑out of Apogee spurred immunology market moves, affecting micro‑cap Cue Biopharma.

12. about 1 month ago

    [BUSINESS] 4 sources

    AbbVie to Acquire Apogee Therapeutics for $10.9 Billion

    AbbVie agreed to buy Apogee Therapeutics for $10.9 bn, adding a pipeline targeting atopic dermatitis and other immune diseases, aiming to broaden its portfolio beyond Skyrizi and Rinvoq.

13. about 1 month ago

    [BUSINESS] 2 sources

    AbbVie posts earnings beat, declares dividend and moves toward $11 billion Apogee deal

    AbbVie beat earnings expectations, raised its dividend and sees its stock up 6%, while moving toward a $10.9 billion acquisition of Apogee Therapeutics.

14. about 1 month ago

    [BUSINESS] 5 sources

    AbbVie seals $10.9 billion purchase of Apogee Therapeutics

    AbbVie agreed to buy Apogee Therapeutics for $10.9 billion, adding its atopic dermatitis drug zumilokibart to AbbVie’s pipeline and marking the third‑largest biopharma deal of the year.

15. 2 months ago

    [BUSINESS] 2 sources

    Apogee Therapeutics garners $1.3 bn Blackstone financing to advance eczema drug

    Apogee Therapeutics secured up to $1.3 bn from Blackstone to fund late‑stage development of its eczema drug zumilokibart, which showed positive mid‑stage trial results but mixed dose performance.

16. 2 months ago

    [BUSINESS] 2 sources

    Crescita Therapeutics Secures Court Approval for Arrangement with ClinActiv

    Crescita Therapeutics wins Ontario court approval for its arrangement with ClinActiv Holdings.

17. 3 months ago

    [BUSINESS] 2 sources

    Aclaris Therapeutics outlines expanded asthma and skin disease trials for 2026

    Aclaris Therapeutics details 2026 clinical milestones for asthma, atopic dermatitis and lichen planus drugs, with cash $190.8M.

18. 3 months ago

    [BUSINESS] 2 sources

    Crescita Therapeutics Shareholders Approve ClinActiv Acquisition

    Crescita Therapeutics shareholders overwhelmingly approved ClinActiv Holdings' acquisition plan.

19. 3 months ago

    [BUSINESS] 2 sources

    Aquestive Therapeutics secures $150 million debt refinancing with Oaktree

    Aquestive Therapeutics refinanced its debt with a $150 million Oaktree facility, funding the potential launch of its Anaphylm allergy treatment.

20. 3 months ago

    [HEALTH] 3 sources

    Acurastem secures $7.5M CIRM grant as Coya Therapeutics gains FDA fast‑track for ALS drugs

    Acurastem gets $7.5M CIRM grant for ALS drug; Coya Therapeutics earns FDA fast‑track status.

21. 3 months ago

    [BUSINESS] 2 sources

    Crescita files circular for special meeting and interim order in ClinActiv arrangement

    Crescita files circular and mails materials for May 14 special meeting; interim order obtained for ClinActiv arrangement.

22. 4 months ago

    [HEALTH] 2 sources

    Circio teams with Acuitas on in-vivo CAR-T approach; UCSF joins Caris Precision Oncology Alliance.

    Circio partners with Acuitas on in-vivo CAR-T; UCSF joins Caris Precision Oncology Alliance.